Arcus Adds Aveo's Tivozanib to Kidney Cancer Combo Trial, Enrollment Q4
RCUS has more than doubled off its 52-week low of $8.84.
Summary
Arcus is expanding its kidney cancer strategy with a second clinical collaboration in a single day. This agreement with Aveo Oncology adds tivozanib to casdatifan in a new ARC-20 cohort, with enrollment starting Q4 2026. It follows the earlier Summit collaboration on a different combination, signaling an aggressive push to establish casdatifan as a backbone therapy in renal cell carcinoma. The deal is structured with Aveo supplying its drug and Arcus sponsoring the study, keeping costs manageable. With the stock near $30 and a $3.8B market cap, pipeline expansion is critical after Q1's revenue decline and trial discontinuations.
At the time of this announcement, RCUS was trading at $29.97 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.8B. The 52-week trading range was $8.84 to $31.74. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.